A reappraisal of loop diuretic choice in heart failure patients
- 6 January 2015
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 169 (3), 323-333
- https://doi.org/10.1016/j.ahj.2014.12.009
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in CardiomyocytesPLOS ONE, 2013
- The past, present and future of renin–angiotensin aldosterone system inhibitionInternational Journal of Cardiology, 2013
- A Two-Symptom Congestion Score In Relation to Outcomes after Discharge with Acute Decompensated Heart FailureJournal of Cardiac Failure, 2013
- Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaJAMA, 2013
- Effects of Prolonged-Release Torasemide Versus Furosemide on Myocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded–End Point, Active-Controlled StudyClinical Therapeutics, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE TrialEuropean Journal of Heart Failure, 2007
- Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failureHeart, 2006
- TorasemidePharmacoEconomics, 2001
- Healthcare Costs of Patients with Heart Failure Treated with Torasemide or FurosemidePharmacoEconomics, 2000